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THE TREATMENT UTILITY OF THE AROUSAL PREDISPOSITION
SCALE IN PREDICTING THE OUTCOME OF EXPOSURE
THERAPY WITH SMALL ANIMAL PHOBIAS
Ellen I. Koch, M.A.
Western Michigan University, 1998
This study evaluated the effectiveness of an in vivo, one-session exposure
procedure modified from that described by Lars-Goran Ost for the treatment of small
animal phobias. This study also assessed the ability of the Arousal Predisposition
Scale to predict treatment outcome. Subjects received treatment for snake, spider, rat,
mouse, or crawling insect phobia. Three groups were utilized (treatment, phobic
control and non-phobic control). The treatment session included both behavioral and
self-report measures of anxiety.

Almost all treatment subjects showed dramatic

improvement on both of these types of measures during posttest and one-month
follow-up.

The treatment and non-phobic control groups were not significantly

different at posttest on behavioral measures. The treatment subjects approached the
animal as much as the non-phobic subjects did and reported symptoms similar to the
non-phobic group at posttest and follow-up signifying a clinically significant
improvement. The phobic control group was significantly different from the other
two groups at posttest. The Arousal Predisposition Scale did not demonstrate a
correlation with treatment outcome.
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CHAPTER I
INTRODUCTION
Statement of the Problem·
Anxiety disorders are one of the single largest groups of mental disorders in
the United States (Pasnau & Bystritsky, 1990). Among the anxiety disorders, phobic
disorders are the most common. Specific phobias involve anxiety reactions elicited
by a circumscribed stimulus (Ost, 1989). Pasnau & Bystritsky (1990) reported one
month prevalence rates of specific phobia for 7.3% of the population. The one year
prevalence rate within the normal population is 9%, according to the Diagnostic and
Statistical Manual of Mental Disorders 4th Edition (DSM-IV) (American Psychiatric
Association, APA, 1994). Lifetime prevalence rates range from 7.8% to 23.3%, as
found in the Epidemiologic Catchment Area Study sponsored by the National
Institute of Mental Health (Robins, Helzer, Weissman, Orvaschel, Gruenberg, Burke
& Regier, 1984). Variations in prevalence rates may be due to difficulty judging
impairment without access to an operational definition, or the difficulty detecting
phobias because of concealed symptoms due to avoidance of the stimuli (Reich,
1986). The diagnosis of a specific phobia depends on the circumstances of the
individual's life (i.e., avoidance of the feared stimulus may or may not interfere with
everyday functioning). An individual may live comfortably avoiding the feared
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stimulus, or may require contact with the phobic stimulus on a daily basis (DeRuiter,
Rijken, Garssen, Van Schaik, & Kraaimaat, 1989). Therefore, some specific phobias
(i.e., insects, mice and snakes) are unlikely to cause significant impairment in
functioning.

This results in few individuals seeking treatment even though the

prevalence rate for these specific phobias is high (Ost, 1989) and effective treatments
are available.
According to the DSM-IV (APA, 1994), animal fears primarily begin in
childhood. Fears of animals are common among children and usually diminish by
age six. Therefore, the age of onset for animal phobias is around age 7 and abnormal
animal phobias probably result in people who do not lose these fears during the
maturation process. Animal phobias tend to occur more frequently in females than in
males (DSM-IV, APA, 1994; Thorpe & Salkovskis, 1997).

Fears can develop

following a traumatic experience, after observing another fearful individual, or
through information transmission (i.e., constant warnings) (APA, 1994).

These

situations serve as conditioning events such that the presence of the specific
conditioned stimulus (i.e., a particular animal) elicits a conditioned arousal response.
Fear may be developed from a single event or from a series of related events (Wolpe,
1990). An example of laboratory conditioning of a fear response occurred with the
11 month old Little Albert. Watson & Rayner ( 1920) paired a rat with a loud noise
and Albert developed a fear response to the sight of the rat. This fear also generalized
to other similar stimuli (i.e., cotton, white hair, etc.).
Exposure therapy has proven successful for alleviating symptoms of specific
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phobia (Chambless, 1990). The goal of exposure therapy involves the conditioned
stimulus eliciting a different conditioned response. The presence of the animal no
longer elicits the heightened arousal or anxiety response. The individual remains in
the feared situation (i.e., in the presence of the animal) until they realize that the
consequences they fear may happen do not occur (Ost, 1997b, 1997a, 1989).
Exposure to the actual stimulus (in vivo) is preferred to imaginal exposure (in
vitro). In vitro exposure only involves "contacting" the feared stimulus imaginally,
which may allow the subject to discontinue exposure by ignoring the stimulus.
Therefore, the therapist cannot detect if imaginal exposure is actually occurring
because he/she can not see the person's images. Furthermore, the subject, not the
therapist, controls the amount and occurrence of exposure, whereas during in vivo
exposure the visual stimulus is more difficult to ignore, allowing the therapist to
control the degree and duration of the exposure occurring. Through controlled and
systematic exposure to the actual stimulus, the therapist focuses on extinguishing the
arousal response in the presence of the feared animal. Throughout treatment, the
individual is exposed to the feared situation until the conditioned stimulus no longer
evokes the arousal response and anxiety is diminished. Skinner ( 1953) stated that,
"Avoidance responses may be interpreted as- in part an escape from the emotional
components of anxiety" (p. 179). Once the anxiety response is extinguished in the
presence of the animal, avoidance of the stimuli is no longer necessary.

The

individual remains in the exposure situation until arousal is reduced without escaping
the anxiety experienced as the conditioned response.
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Usually subjects experience an increase in arousal during exposure treatments.
It is unclear if the heightened arousal that occurs during confrontation with the feared
stimulus inhibits or facilitates treatment outcome. Williams, Turner, & Peer (1985)
indicated that anticipated anxiety predicted treatment effects when performance
anxiety and perceived danger were controlled for in individuals with height phobia.
Another aspect of this study viewed desensitization and flooding as two different
forms of treatment with the one difference between these treatment approaches being
the levels of anxiety experienced, i.e., low levels of anxiety for desensitization and
high anxiety levels for flooding (Williams et al., 1985).

Both of these treatment

approaches have been demonstrated to be effective despite this difference in anxiety
levels during treatment.
In a study conducted by Stekette, Bransfield, Milier and F oa (1989), the
researchers assessed the amount of reduction of phobic anxiety that occurs during
treatment for 33 subjects with animal phobia that seek versus avoid information. The
authors found that those who monitored their environments and sought information
were more aroused during baseline than subjects that avoided information and that
pretreatment arousal did not affect treatment outcome. While both groups improved
following treatment, the authors indicated that the information seekers reduced
anxiety levels more quickly than the other group. The researchers reported that the
information avoidance group did not fully engage in the exposure situation as a way
to prevent heightened anxiety, which delayed treatment effects.

The authors

concluded, "It is possible that moderate, rather than high or low arousal, would
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enhance anxiety reduction" (Steketee et al., 1989, p. 82). However, in a comparable
study Lader, Gelder, and Marks (1967) concluded that lower pretreatment arousal
would lead to a more improved treatment outcome. It is clear that conflicting studies
assessing the effects of arousal level on treatment outcome occur and that further
experimentation is required.
Review of Related Literature
Research With Regard to One-Session Exposure
Variations of exposure treatment have reduced symptoms of anxiety disorders
in general and specific phobias in particular. Recent studies have shown an effective
exposure treatment for specific phobias that involves only one session (Hellstrom &
Ost, 1995; Ost, Salkovskis, & Hellstrom, 1991; Ost, 1989, 1987, 1985).

This

treatment involves a maximum of three hours and utilizes prolonged, in vivo
exposure and participant modeling to the feared stimulus (Ost, 1989, 1987). The
subject consents to remain in the exposure situation until anxiety diminishes, which
involves approaching the feared stimulus, allowing anxiety to diminish, and
continuing to approach the stimulus more closely (Ost, 1989).

The therapist

continually demonstrates how the subject should interact with the feared stimulus.
The subject gradually contacts the object by initially touching the therapist as the
therapist touches the feared object and approaching full contact with the stimulus
alone. The subject begins to interact with the object more and more with the therapist
merely present in the room (Ost, 1989).
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Individuals suitable for this treatment include those with circumscribed
phobias for one specific situation or object (animal phobias are particularly
appropriate), as well as those with the motivation to alleviate symptoms of phobia and
willingness to tolerate possible anxiety during the treatment. The inclusion criteria
employed by Ost (Hellstrom & Ost, 1995; Ost, et al., 1991; Ost, 1989, 1987, 1985)
were that subjects should not be receiving positive consequences for their phobia and
no predictable negative consequences should occur if the phobia is treated.
Single-session exposure treatment was first employed for one case of injection
phobia with 12 years duration (Ost, 1985). This session took 90 minutes to complete
with heart rate and subjective anxiety measures taken throughout the session. The
positive effects of treatment for this individual generalized to other injection
situations and results were maintained for at least 4 years following treatment.
Ost ( I 987) then utilized one-session exposure to treat multiple specific
phobias. A multiple baseline design was used with three one-session treatments.
Little to no generalization effects were seen across phobias. However, generalization
to the natural setting for treated phobias was observed.

"A clinically meaningful

change took place only when treatment was directed at the phobia in question, not
when some other of the phobias were treated," (Ost, 1987, p. 183).

These

improvements were maintained at a 6-month follow-up.
In another study Ost (1989) conducted one-session exposure treatment for 20
subjects with various specific phobias (i.e., injection, spider, rat, cat, bird, and dog)
with an average of 2.1 hours of therapy. Results indicated that 90% of the subjects
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showed a clinically significant improvement (much improved or completely
recovered), which was maintained through follow-up (4 year average) (Ost, 1989).
In 1991, Ost et al. compared therapist-directed exposure to self-exposure for
spider phobia.

This study demonstrated that therapist-directed exposure was

significantly better than self-directed exposure at post-treatment and 1-year follow
up.

Also at post-treatment and follow-up, 71% of the therapist-directed group,

compared to 6% of the self-directed group, displayed clinically significant
improvements.

Furthermore, 88% of the individuals in the therapist-directed

treatment, compared to 13% in the self-exposure group, were able to complete the
entire behavioral avoidance test at post-treatment and follow-up.
One-session therapist directed exposure was also superior to two forms of
manual (specific spider and general manual) directed self-exposure (Hellstrom & Ost,
1995).

Therapist-directed treatment was significantly more effective than the

manual-based treatments at post-test and follow-up.

Of the individuals in the

therapist-directed group, 80% showed clinically significant improvements at follow
up.
Yet another study by Ost, Hellstrom, & Kaver ( 1992) compared one-session
exposure to five-session exposure for injection phobia. The average treatment time
for the one-session exposure was 2 hours whereas for the five-session- exposure the
average time was 3 hours and 32 minutes. Both groups improved significantly on all
measures (including measures of clinical significance) and effects were maintained at
a 1-year follow-up. At the follow-up, 90% of the one-session group and 84% of the
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five-session group were clinically improved.
It should be noted that no subject has ever been harmed physically,
psychologically, or socially from completing this treatment (Ost, 1985, 1987, 1989;
Ost et al., 1991; Ost et al., 1992; Hellstrom & Ost, 1995). None of the subjects
treated with one-session exposure dropped out during treatment. This is impressive,
given that drop out rates generally tend to be high when exposure procedures are
utilized. Ost postulates that it is probable that this treatment is effective because
catastrophic thoughts concerning the phobia are tested to the extent that anxiety is no
longer present within a specific situation/setting (Ost et al., 1991 ). In addition, the
one-session treatment is economical and not limited by the return of fears between
sessions, which may occur with other treatments that involve more sessions (Ost et
al., 1992).
One goal of the exposure treatment session involves the subject managing
within the natural environment when confronted with the phobic object (i.e., spider
phobic is able to remove a spider from the home), achieving a normal, non-phobic
relationship to the feared stimulus.

A second goal involves a large amount of

"overlearning" where treatment goes beyond the first goal (Ost, 1989). This requires
that the subject be comfortable interacting -with the feared stimulus beyond the
amount required to remove the stimulus from the environment. The subject allows
the stimulus to crawl on both hands, for example. The subject is demonstrating that
he/she is capable of more than the minimal requirement for "normal" functioning.
Although, the subject may be unaware of the second goal, the therapist needs to
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continually work towards that goal (Ost, 1989).
The work conducted by Ost outlined above demonstrates the effectiveness of
the one-session exposure procedure. This treatment has been utilized with a variety
of different specific phobias and under different conditions (i.e., manual vs. self
directed treatment, one vs. five-session treatment, etc.)._ In every study, Ost utilizes a
conventional test for clinical significance. He indicates that a change of at least two
standard deviations improvement from pretest to posttest represents a clinically
significant shift due to the treatment procedure.

An additional guideline for a

clinically significant improvement outlined in the Manual for the 1-session treatment
of specific phobia (Ost, 1997b) involves an individual being able to touch a one-inch
spider with bare hands. Neither of these procedures demonstrates whether or not the
individual subject is within a non-phobic range with respect to the dependent
measures following treatment.
Ost's work utilizes cognitive interventions to facilitate change as well (Ost,
1997b and Ost, 1997a). A portion of the treatment procedure involves counteracting
the catastrophic beliefs elicited by contact with the feared stimulus (Ost, 1997b). Ost
(1991) indicates that,
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the most important factor in I -session treatment is making

explicit the patient's catastrophic thoughts - concerning the phobic situation and
devising the exposure situation in such a way that these can be tested out, (p. 421 ).
11

However, the influence and necessity of the cognitive interventions within one
session exposure has not been empirically demonstrated within Ost's line of research.
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Research With Respect to the Arousal Predisposition Scale
The Arousal Predisposition Scale (APS) (Coren, 1988) was developed under
the premise that insomnia might be predictable from the concept of cognitive arousal,
involving a long term behavioral predisposition or trait. Coren (1990) states that,
" ... an individual manifests different degrees of arousal under varying conditions.
This individual difference dimension of arousal may be viewed as a predisposition
toward arousal, and we will call this trait arousability" (p. 551).

Coren (1988)

established the APS as a valid and reliable indicator of sleep disruptions and
insomnia. Coren (1990) presented normative data for use with the APS. Even though
the APS was developed to measure individual differences in arousability and
validated against insomnia, generalization of arousability may allow measurement of
differences based on environmental stressors (Coren, 1990).
Coren & A.ks (1991) demonstrated that subjects with a high APS measure of
arousability showed a greater change in task-related arousal than subjects low on
arousability. Scores on APS predicted arousal under conditions of stress (speeded
task performance with distracting stimuli) for the authors.

Therefore, individuals

with high arousability showed a greater increase in arousal than individuals judged to
be low in arousability (Coren & Aks, 1991 ), suggesting a general trait or
predisposition toward arousability.

This measure may be utilized to assess

differences in arousability leading to a prediction of individual reactions to stressful
environmental conditions.
In 1993 Coren & Mah demonstrated a correlation between APS and
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physiological measures of arousability. Coren & Mah (1993) reported, "Subjects who
scored highly arousable on the APS showed a greater change in electrodermal and
electromyographic response than subjects judged low on arousability" (p. 215).
Hence, high APS scores predict greater degrees of physiological arousal than do low
APS scores and the APS is capable of predicting individual differences in
physiological arousal.
Purpose of the Present Study
This study evaluated a purely behavioral treatment for small animal phobias to
determine the effectiveness of one-session exposure treatment without utilizing the
cognitive interventions outlined by Ost (1989, 1997a, 1997b). An endstate level of
functioning for the treatment group compared to a group of non-phobic individuals
was also conducted. This comparison provided a test of clinical significance that
utilized a "normal" range of scores to determine if the treatment subject's performance
was within this range following treatment. Further, this study considered the ability
of the APS to predict treatment outcome to determine which subjects would receive
the greatest benefit from treatment. Finally, the process of change throughout the
treatment session was demonstrated through 1he use of subjective units of distress,
which allowed the subject to rate subjective anxiety throughout treatment.
To test the effectiveness of a modified Ost treatment procedure, the present
study employed a pretest-posttest design that featured a treatment group and a phobic
control group. The phobic control group did not receive the one-session exposure
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treatment, but did complete the Behavior Avoidance Test (BAT) during the
"treatment" session. A non-phobic control group completed the dependent measures
at pre- and posttest for comparison with the treatment group results.
The present study tested the hypothesis that the modified one-session
exposure treatment would alleviate the symptoms of specific phobia. Also tested was
the hypothesis that APS would predict treatment outcome.
The dependent variables utilized involved behavioral and self-reported
measures of anxiety. The behavioral measures consisted of the distance and duration
measures of approach to the animals, which constituted the Behavioral Avoidance
Test (BAT). The self-report measures included the Fear Survey Schedule (Wolpe &
Lang, 1977), Spider Phobia Questionnaire (Watts & Sharrock, 1984) or other specific
animal phobia questionnaires developed by the authors based on the Spider Phobia
Questionniare, Symptom Checklist 90 Revised (SCL-90-R, Derogatis, 1983) phobic
anxiety and anxiety subscales, Structured Clinical Interview for DSM-IV Axis I
Disorders - Non-Patient Edition, Version 2.0 (First, Spitzer, Gibbons, Williams,
1996) specific phobia section, and subjective rating of expected success of treatment.
Additionally, the therapist's rating of phobia severity and Subjective Units of Distress
(SUDs, Wolpe, 1990) were completed during the BAT (see Appendix A for scales).

CHAPTER II
METHODS
Subjects
Thirty-three subjects (20 treatment subjects and 13 phobic control subjects)
volunteered to participate in this study (see Appendix B for Human Subject
Institutional Review Board approval letter). Subjects were recruited from college
classes, newspaper advertisements, and public postings (see Appendix C for
recruitment flyer and classroom solicitation script). Subjects were selected from a
pool of male and female individuals who, according to their own report were afraid of
small animals. The subjects indicated that they avoided contact with the particular
animal and/or experienced extreme distress in the presence of the animal.
All participants included in the study possessed phobic symptoms for at least
6 months. The animal fears targeted for this study were snake, spider, rat, mouse, and
crawling insect.
Potential subjects were included only if they met diagnostic criteria for
specific phobia - small animal type based on the Structured Clinical Interview for
DSM-IV Axis I Disorders - Non-patient Edition (SCID-1/NP, Version 2.0) (First,
Spitzer, Gibbon, & Williams, 1996). Potential subjects were excluded if they (a) had
a history of organic illness or heart disease; (b) were capable of direct contact with
13
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the feared stimulus during the baseline session; (c) met diagnostic criteria for Panic
Disorder, Post-Traumatic Stress Disorder related to the particular animal, or
Psychosis; or (d) did not meet diagnostic criteria for the specific animal phobia.
During the first session, 20 subjects were excluded from participation based on these
criteria. Seven subjects were excluded based on various health conditions such as
migraines, ulcer, heart condition, neurological problems, etc.

Six subjects were

excluded because they did not meet the diagnostic criteria for specific phobia, and 3
subjects were able to handle the "feared" animal during baseline.

Four subjects

received other diagnoses that led to exclusion (i.e., panic disorder).

Other

exclusionary criteria utilized involved: (a) unavailable throughout the follow-up
period; (b) unmotivated to get rid of fear; (c) intolerable of possible anxiety during
treatment; (d) currently receiving positive consequences due to the phobia; or (e)
receiving predictable negative consequence if phobia is treated. The last two criteria
assessed the subject's motivation for reducing their animal phobia. No subjects were
excluded based on these criteria.
For the treatment subjects, the first three sessions were conducted
approximately one week apart and a one-month follow-up occurred. The first session
consisted of the assessment session to determine if the subject qualified for the study,
the second session was the treatment session, and the third and fourth sessions were
posttest and follow-up assessment sessions. The first three sessions for the control
subjects were identical to the treatment subjects excluding one-session exposure
treatment during the second session where the subject completed the BAT only.
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Design
A two-factor repeated measures design was used. The between subject factor
consisted of treatment vs. no treatment and the within subject factor constituted the
pretest and posttest administrations of each dependent measure.
Procedures
Setting
All assessment and treatment sessions were conducted in therapy rooms
within the Research Commons Area of The Department of Psychology.

A room

measuring approximately 14' x 21' was used for treatment sessions and an individual
therapy room measuring approximately IO' x 11' for screening sessions. A large
ruler extending from the doorway to the far wall was placed on the floor of the larger
room. Against the far wall a small table was located with a 20-gallon container
(measuring 18" high x 1O" deep and 20" across) on top (see diagram of room layout
in Appendix D), which contained the feared animal. Each subject approached the
animal cage by walking on the ruler.

An observer behind a one-way mirror

videotaped all behavioral assessments.
Apparatus
Equipment used during the baseline, treatment, posttest and follow-up
behavior avoidance test assessment sessions included a Sony videocamera,

16
microphone, digital stopwatch, large ruler, clock, and animal cage. All behavioral
assessment sessions were videotaped and the microphone recorded sounds within the
treatment room. The stopwatch measured duration of the behavioral assessments
during all trials and the large ruler determined the distance between the subject and
the feared animal throughout treatment and BAT sessions. The clock was used to
record total treatment duration.
Measures
Each subject's level of anxiety was measured according to the following self
report measures: (a) Fear Survey Schedule (FSS, Wolpe & Lang, 1977); (b) Spider
Phobia Questionnaire (Watts & Sharrock,

1984) or other specific phobia

questionnaire (i.e., snake, mouse/rat and crawling insect); (c) Symptom Checklist 90Revised (SCL-90-R, Derogatis, 1983) phobic anxiety and anxiety subscales; (d)
Structured Clinical Interview for DSM-IV Axis I Disorders - Non-patient Edition
(SCID-IINP, Version 2.0) (First, Spitzer, Gibbon, & Williams, 1996) specific phobia
section; (e) subjective .ratings of expected success of treatment; ( f) therapist's rating of
phobia severity; and (g) Subjective Units of Distress (SUDs, Wolpe, 1990).
The Fear Survey Schedule (FSS, Wolpe & Lang, 1977) is a self-report
questionnaire in which the subject rates situations that may cause fear or unpleasant
feelings on a scale from 0 (not at all) to 4 (very much). The FSS utilizes ratings for
108 different specific phobias. The test-retest reliability has been found to be 0. 72
(Wolpe & Lang, 1977). Klieger & Franklin ( I 993) report that reliability of the FSS
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has ranged from 0.62 to 0.84.

Assessing the validity of the FSS has involved

correlating Galvanic Skin Response and FSS scores.

Utilizing the FSS allows

assessment of possible changes in the specific animal phobia following treatment, as
well as comparison of results with previous studies.

In this study the FSS was

administered at pretest and posttest to all subjects and .at follow-up to the treatment
subjects.
The Spider Phobia Questionnaire (SPQ, Watts & Sharrock, 1984) contains 43
questions to which the subject responds with "yes" or "no". Answering "yes" scores
one point for many of the questions, except for items 2, 10, 13, 29, and 42, in which
"no" is scored with one point.

This measure assesses dimensions of vigilance,

preoccupation, and coping-avoidance (Watts & Sharrock, 1984). External validity
studies confirm the use of these three subscales. "The three scales perform equally
well in distinguishing individuals with phobias and normals, and in showing
improved scores as a result of desensitization" (Watts & Sharrock, 1984, p. 580).
Other specific fear measures (snake, rat or mouse and crawling insect) modeled
questions from the SPQ (Watts & Sharrock, 1984) and were developed by the
researchers. Each of these questionnaires contained 38 items that the subject answers
with "yes" or "no". Again, answering "yes" -scores one point except for items 2, 9,
11, 25, and 37, in which "no" is scored with one point.
Specific fear questionnaires generally report high internal consistencies
(Fredrikson, 1983). Fredrikson (1983) reported that individuals with phobia score
higher on their specific phobia scale (Spider Phobia Questionnaire and Snake Anxiety
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Questionnaire) than a control group and did not differ from controls on other scales
(public speaking, mutilation, etc.). Correlation between fear ratings and questionnaire
scores is significant and utilizing such scales to evaluate therapeutic change ts
encouraged (Fredrikson, I 983). The specific fear measures were administered at
pretest and posttest for all subjects and at follow-up for the treatment subjects. These
scales are utilized to measure changes related to the particular animal fear over time.
The Symptom Checklist-90-Revised (SCL-90-R, Derogatis, I 983) measures
current psychological symptom status on nine dimensions and three global indices of
distress. Each of the 90 items is rated on a 5-point Likert scale of distress ranging
from 0 (not at all) to 4 (extremely). Internal consistency coefficient for the symptom
clusters range from 0.77 (psychoticism) to 0.90 (depression) and the test-retest
reliability ranges from O'. 79 (hostility) to 0.90 (phobic anxiety) (Derogatis, I 983).
Anxiety and phobic anxiety subscale scores were utilized in this study at pretest and
posttest for all subjects and at follow-up for the treatment group.

These scales

assessed changes pertaining to global symptoms of phobic anxiety and anxiety over
time.
The Structured Clinical_ Interview for DSM-IV Axis I Disorders - Non-patient
Edition (SCID-1/NP, Version 2.0) (First, Spitzer, Gibbon, & Williams, 1996) is a
broad-based structured clinical interview that covers 50 major DSM-IV disorders.
The screening questions allowed the administrator to skip sections when essential
criteria for a diagnosis are not met.

The sections utilized in this study included

psychotic, mood, anxiety, and somatoform disorders.

Reliability for diagnostic
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instruments, 1.e., SCID-I/NP, has been obtained by comparing the independent
evaluation by two or more raters across a group of subjects. However, since the
SCID-I/NP is not a fully structured interview and depends on clinical judgment, the
reliability is a function of the circumstance in which it is being used (Spitzer,
Williams, Gibbon, & First, 1990). One study demonstrated a kappa coefficient of
0. 74 for the interview as a whole (Riskind, Beck, Berchick, Brown, & Steer, 1987).
Validity for diagnostic instruments involves comparing the assessment diagnosis with
some hypothetical standard. Riskind et al. (1987) found that the SCID could reliably
distinguish between patients with generalized anxiety disorder and major depressive
disorder. Therefore, the SCID-I/NP appears to be reliable and valid and was used to
screen out individuals diagnosed with panic disorder as well as ensure that the phobic
subjects met diagnostic criteria for specific phobia. The specific phobia section of the
SCID-I/NP was also administered to all subjects during the posttest session and at
follow-up for the treatment subjects.

This interview was utilized to assess if

diagnostic criteria were met for specific phobia at pretest, posttest and follow-up.
Behavioral Avoidance Test
The behavioral avoidance test (BAT} involved the subject approaching the
feared animal as much as possible until their fear was intolerable (see Appendix E for
instructions) following an instruction to "Approach the animal as much as you
possibly can and pick the animal up gently when you are ready." At the subject's
stopping point, the assistant asks "Are you sure that is as far as you can go, today?"

This statement provided a challenge for the subject without undue pressure to make
sure an optimal performance level is reached. The assistant recorded the duration of
the test from beginning to end, distance between the subject and the animal, actual
contact time with the animal and the subject's overt responses (e.g., turning away,
shaking, etc.) (see Appendix A for observer data collection form). The distance was
recorded according to the BAT scoring steps (Appendix F). Following the mild
challenge, the subject reported a current SUDs level at the stopping point.

The

maximum level for the BAT was holding the animal for at least 60 seconds. The
subject was then removed from the room and asked, "Would you like to try one more
time to see how far you can go? " If the subject chose to try again, the procedure
outlined above was repeated.
Subjective Measures
Each subject reported their expected success of treatment on a scale from 1
(extremely skeptical) to 5 (extremely confident) and the therapist rated the phobia
· severity on a scale from 1 (symptom free and not disabling) to 5 (extremely severe
and disabling).

Subjective Units of Distress (SUDs) ratings were given by the

subjects on a O (least anxious the individual has ever been in relation to this animal)
to 100 (most anxious the individual has ever been with this animal) scale. These
measures were taken during all of the behavioral assessments (Appendix A).
Objective measures were utilized during the BAT as well.

The subject's

distance (i.e., proximity to the animal), duration (i.e., time until the SUDs rating) and
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amount of actual contact with the animal were recorded. The SUDs ratings were used
to assess the subject's comfort level with the specific animal.
The Arousal Predisposition Scale (APS, Coren, 1988) provided a measure of
arousal for comparison with treatment outcome. The APS (Coren, 1988) consists of
12-items.

The subject selected the response that best applied to them and their

behavior for each of the 12 statements based on a "never" to "always" scale. All
items on the APS are scored in ascending sequence ("never" equal to 1 up to
"always" equal to 5) with the exception of number 1, which is reverse scored. An
individual's score is simply the sum of the responses for the 12 items. The APS is
demonstrated to have high internal consistency with an alpha of 0.84 (Coren, 1988).
The APS was administered at pretest and posttest to all subjects and at follow-up for
the treatment group. This measure was utilized to assess the ability of the APS to
predict treatment outcome.
Procedure
During the first session (see Appendix E for first session instructions) the
subject read and signed the informed consent (Appendix G), answered the questions
on the screening questionnaire (Appendix H)·and completed the APS. The research
assistant interviewed the subject on the screening questions, which covered some of
the exclusionary criteria.

The research assistant then administered the Structured

Clinical Interview for DSM-IV Axis I Disorders - Non-patient Edition (SCID-1/NP,
Version 2.0) (First, Spitzer, Gibbon, & Williams, 1996). Each subject completed the

FSS, a specific fear measure for his/her small animal fear and the SCL-90-R.
The BAT was completed following the questionnaires. A research assistant
explained that the subject would enter another room (large room within the Research
Commons Area) that contained the feared animal within an enclosed cage. The cage
was placed on a table against the wall furthest from the doorway. Placed on the floor
was a large ruler with numbers specifying the distance between the subject and the
feared stimulus. The BAT constituted an objective measure of performance. The
treatment subjects completed the BAT during baseline, again immediately following
treatment, a third time during the posttest, and finally at the one-month follow-up
session. The control subjects finished the BAT at baseline, "treatment", and posttest.
Finally, the subject rated his/her expected success of treatment and the
assistant rated the severity of the subject's phobia (see Appendix A for both rating
scales). The BAT was videotaped for each subject to permit accurate data collection
and reliability ratings.
The treatment session was scheduled approximately one week after session
one. All treatment subjects received the one-session exposure treatment (see
Appendix I for treatment session instructions and Appendix J for treatment guidelines
for each animal). Jhe subject was asked to watch the therapist complete each small
step and then either complete that step along with the therapist or on their own. Each
subject progressed through the treatment steps with the therapist providing
instructions and modeling for each step. The subject was instructed to signal for a
break by saying "pause" instead of moving abruptly or dropping the animal. The
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therapist waited for one minute after the subject asked for a pause to resume
treatment.
The termination criteria for the treatment session involved completing the
treatment steps with little to no reported subjective anxiety, being unable to proceed,
or reaching the three-hour session time limit. The treatment steps were recycled until
all of the SUDS were below 20 for the steps completed.

The final step of the

treatment involved holding the animal for at least 60 seconds. Following treatment,
the subject was asked to exit the room and complete the BAT from the start. The
instructions and procedures for the BAT were the same as outlined above.

The

control subjects completed the BAT only and not the one-session exposure treatment
during this second session.
The posttest session was approximately one week after the second session for
both groups (see Appendix K for instructions). This session consisted of the subject
completing the APS, SCL-90-R, FSS, and a specific fear measure for the subject's
phobia. The research assistant interviewed the subject on the SCIO-I/NP specific
phobia section. Two separate interviews occurred; one pertaining to the treatment
animal in particular and the second pertaining to types of the animal in general.
These separate interviews were used to assess generalization to other animals of the
same type (i.e., to other snakes and spiders) as well as treatment effects with the
specific animal. The BAT was conducted as outlined above. Finally, the subject
rated their judgement as to the success of treatment and the assistant rated the phobia
severity. All subjects were offered the opportunity to view their videotape from

previous sessions at the end of the posttest session. The treatment subjects were also
offered the opportunity to practice with the animal between posttest and follow-up.
The control subjects were offered the one-session exposure treatment following the
third session.

The treatment subjects completed a one-month follow-up session,

which involved the same procedures as the posttest session without the videotape
viewing and practice options (see Appendix K for instructions)
A group of thirty non-phobic subjects were screened based on the same
criteria listed previously except that the subject could not possess symptoms of
specific phobia for the particular animal targeted. This group of non-phobic control
subjects completed the FSS, specific phobia questionnaire, SCL-90-R, APS, and BAT
(including distance, duration, therapist rating of phobia severity, and SUDs measures)
at pretest and posttest (see Appendix L for instructions and forms). The two sessions
were conducted approximately two weeks apart. This group provided a comparison
of "normal" performance on these measures with the treatment group at posttest and
follow-up.
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CHAPTERIII
RESULTS
Preliminary Analysis
Eight individuals who were selected to participate did not complete the study.
All eight of these subjects dropped out of the study between the first session and the
treatment session. Two treatment subjects did not complete the one-month follow-up.
The 63 subjects who completed the study were primarily college students and female
(see Table 1 for the demographic data on the subjects).
Table I
Frequency and Percentage of Demographic Characteristics Between Groups

Sex

Male
Female
Current Student
Yes
No
Animal Type
Snake
Spider
Rat
Crawling Insect
Mouse

TREATMENT
GROUP

PHOBIC
CONTROL GROUP

NON-PHOBIC
CONTROL GROUP

4(20%)
16(80%)

4(30.8%)
9(69.2%)

10(33.3%)
20(66.7%)

17 (85%)
3(I 5%)

7- (53.8%)
6(46.2%)

27 (90%)
3(10%)

10 (50%)
5(25%)
4(20%)
I (5%)
0

7 (53.8%)
6(46.2%)
0
0
0

6(20%)
6(20%)
6(20%)
6(20%)
6(20%)
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Reliability of the BAT Assessment
Interobserver agreement for scores on the BAT was taken during 21% of the
sessions for phobic subjects and 12% of the sessions for non-phobic subjects. The
overall interrater reliability for the phobic subject's BAT total duration was .92 and
.85 for distance. The overall interrater reliability for the non-phobic subjects was .87
for duration and 1.0 for distance. The interrater reliability on the therapist's rating for
severity of phobia was .80 for the phobic subjects and .89 for the non-phobic subjects.
Diagnostic Outcomes
All phobic subjects met DSM-IV diagnosis for specific animal phobia with
the utilization of a lenient E criterion (e.g., the phobia interferes significantly with the
person's normal routine) (AP A, 1994). None of the non-phobic subjects endorsed
symptoms of specific phobia related to the animal selected. The length of animal fear
in years for the phobic subjects ranged from 5 to 38 for the treatment subjects and
from 8 to 65 for the phobic control subjects. Five subjects in both the treatment
group and the phobic control group met diagnostic criteria either currently or in the
past for other disorders, i.e., social phobia, obsessive-compulsive disorder,
agoraphobia without panic disorder, major depressive disorder, generalized anxiety
disorder, substance-induced mood disorder, or post-traumatic stress disorder.
At posttest, 19 of the treatment subjects no longer met diagnostic criteria for
specific phobia in relation to the specific animal from treatment and 10 of these
subjects also did not meet criteria for specific phobia related to other types of that
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animal. Whereas in the phobic control group, 10 of the subjects still met diagnostic
criteria for specific phobia in relation to that specific animal and all 13 subjects met
criteria for that animal type in general.

All 18 of the treatment subjects that

completed follow-up did not meet the diagnostic criteria for specific phobia related to
the specific treatment animal and 14 out of the 18 subjects did not met criteria for that
animal type in general.
Treatment Outcomes
For the treatment group, 16 out of the 20 subjects met the terminal criteria for
success, i.e., completed all steps with little or no anxiety including holding the animal
for at least 60 seconds. Of the four subjects who did not successfully meet terminal
criteria, 2 subjects terminated prematurely, 1 subject completed all but 2 steps with
little or no anxiety and 1 subject reached the 3-hour limit and treatment was
terminated. Three out of the four of these subjects made substantial improvements
during treatment even though the terminal criteria were not met. Only one subject did
not improve following the treatment and this subject terminated treatment after 20
minutes.
Ten of the treatment subjects (50%) -and IO of the phobic control subjects
(76.9%) opted to watch their videotape at posttest.

Only I treatment subject

participated in the offered practice sessions. All of the subjects indicated that they do
not use drugs or alcohol to help relieve anxiousness caused by their phobia.
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To assess the equivalency of the dependent measures at pretest a One-way
Analysis of Variance was conducted for all 3 groups and Tukey tests were ran for
each comparison. The treatment group and the phobic control group were equivalent
on all dependent measures at pretest. Further all three groups were equivalent on the
APS and the SCL-90-R Anxiety subscale at pretest. The treatment group and the
non-phobic control group were equivalent on the SCL-90-R Phobic Anxiety subscale,
but the phobic control group was significantly different than the non-phobic control
group on this measure at baseline (Q = .037). Both of the phobic groups differed
significantly from the non-phobic group on the FSS, specific fear questionnaire, BAT
baseline distance, BAT SUDs and therapist's rating of phobia severity. All of the
significant differences were in the direction of the non-phobic group having less
dysfunction.
Primary Analyses
A repeated measures analysis of variance was conducted on the pretest and
posttest scores for the treatment and the phobic control groups on each dependent
measure. An analysis of variance with multiple comparisons was conducted on the
posttest scores between all three groups. One-sample t-tests were computed for the
treatment subjects comparing posttest to follow-up scores on the dependent measures.
Finally, a correlation was computed between the APS as well as the subject rating for
expected success of treatment and the change scores for the dependent measures.

The scores on the specific phobia questionnaires were weighted for all
analyses to account for the differences between number of questions on each (i.e., the
Spider Phobia Questionnaire has 43 questions and the other specific phobia
questionnaires each have 38 questions).
Table A (see Appendix M) displays the group means and standard deviations
across conditions for each questionnaire dependent measure. The group means and
standard deviations for the BAT dependent measures across all four trials (i.e.,
baseline, treatment, posttest, and follow-up) are displayed in Table B (see Appendix
N).
For each of the dependent measures, the data will be presented first
graphically in figures for visual inspection. The graphs are not consistent across the
y-axis dimension due to different scaling for each measure. Following the visual
analysis the appropriate statistical analysis will be described and displayed in table
form.
Figure 1 displays the group mean changes from pretest to posttest for the FSS.
Upon visual inspection, the groups appear to be different at posttest. The statistical
analysis confirmed that the treatment and the phobic control subjects differed
significantly (Q = .004) at posttest (Table 1).

The treatment subjects improved

significantly on this measure following treatment, whereas the phobic control subjects
did not show improvement on this scale.
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Figure 1. Fear Survey Schedule - Pretest to Posttest Change in Group Means.
Table 2
FSS Results for Repeated Measures ANOY A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig.

18.848
30.428

1
31

18.848
.982

19.202

.000

18.214
4.333
13.974

1
1
31

-18.214
4.333
.451

40.408
9.612

000
.004

Figure 2 displays the differences between the group means from pretest to
posttest on the specific phobia questionnaire.

The posttest scores appear to be

significantly different between the two groups. Statistical analysis confirms that this
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difference is significant (Q = .004, Table 3). The results on this questionnaire are the
same as the FSS above in that the treatment group changed significantly following
treatment, whereas the phobic control group did not change.
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Figure 2. Specific Animal Phobia Questionnaire - Pretest to Posttest Change m
Group Means.
Table 3
Specific Animal Phobia Questionnaire Results for Repeated Measures ANOY A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig

599.409
2563.101

1
31

599.409
82.681

7.250

.011

526.649
164.867
526.488

1
1
31

526.649
164.867
16.983

31.010
9.708

.000
.004
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Figure 3 demonstrates the change between pretest and posttest group means
on the SCL-90-R anxiety subscale. The groups did not appear to be different at
posttest and this was confirmed through statistical analysis (12 = .52, Table 4). Neither
group made a significant change on this measure.
64
60

56

�

52

48

Non-Phobic
Control Group

:

.__

44

-Treatment Group

�Phobic Control Group
40 -+------------------------,
SCL-90-R Anxiety Posllest Score
SCL-90-R Anxiety Pretest Score
T ri:i I

Figure 3. SCL-90-R Anxiety Subscale - Pre- Posttest Change in Group Means.
Table 4
SCL-90-R Anxiety Subscale Results for Repeated Measures ANOV A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Si_g.

56.311
4533.629

1
31

56.311
146.246

.385

.539

30.462
21.189
1566.629

1
1
31

30.462
21.189
50.536

.603
.419

.443
.522
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The SCL-90-R Phobic Anxiety subscale produced similar results as the
Anxiety subscale. Figure 4 displays the differences between means for both groups.
These differences were not significant (12 = .87, Table 5). Neither of the SCL-90-R
subscale scores changed significantly from pretest to posttest.
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I
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Posth:st Score

SCL-90-R Phobic Anxiet\"
Pretest Score

Trial

Figure 4. SCL-90-R Phobic Anxiety Subscale - Pre- Posttest Change in Group Means.
Table 5
SCL-90-R Phobic Anxiety Subscale Results for Repeated Measures ANOV A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig.

27.825
2972.660

1
31

27.825
95.892

.290

.594

24.849
.667
765.090

1
1
3I

24.849
.667
24.680

1.007
.027

.323
.870
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Figure 5 demonstrates the change in BAT distance across three trials (i.e.,
pretest, treatment, and posttest). The treatment group changed significantly (Q < .001)
from pretest to posttest when compared to the phobic control group (Table 6). The
Greenhouse-Geisser correction was utilized to control for sphericity. The treatment
group handled the animal during the treatment and posttest BAT sessions and the
control group did not interact directly with the animal during these points in time.
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BAT Posttest
Distance

T ria I

Figure 5. BAT Distance Scores - Change in Group Means Across Sessions.
The SUDs ratings for the above distances are displayed in Figure 6.

The

treatment subjects showed a significant decline m reported SUDs from pretest to
posttest (Q = .002) compared to the phobic control group (Table 7). The Greenhouse
Geisser was utilized to control for problems related to sphericity. The treatment
subjects advanced significantly further on the BAT at treatment and follow-up and at
the same time reported lower SUDs ratings than the control subjects.
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Table 6
BAT Distance Score Results for Repeated Measures ANOV A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig.

1190.451
1126.955

1
30

1190.451
37.565

31.690

.000

1788.797
855.714
759.474

1.733
1.733
51.983

1032.341
493.845
14.610

70.659
33.802

.000
.000

100
90
80
70
60
50

�Treatment Group
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40
30
20
10
0
BAT SUDs Pretest
Score

BAT SUDs
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BAT SUDs Posttcst
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Trial

Figure 6. BAT SUDs Scores - Change in Group Means Across Sessions.
Each subject reported a SUDs score from the baseline distance point at both
the treatment and the posttest sessions. Figure 7 demonstrates the treatment and
phobic control group's reduction in their average SUDs from baseline to treatment
and posttest. This change was significant (I? = .017, Table 8) with the Greenhouse-
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Geisser correction. The baseline level SUDs score was significantly reduced over
time for the treatment group.
Table 7
BAT SUDs Results for Repeated Measures ANOVA
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig.

13301.911
23611.379

1
29

13301.911
814.185

16.338

.000

6855.298
7039.771
27186.100

1.699
1.699
49.279

4034.242
4142.802
551.677

7.313
7.509

.003
.002

100
90
80
70
60

so

40
30
1

20
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....,_Phobic Control Group

Bascline BAT
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Figure 7. Baseline SUDs Scores - Change in Group Means Across Sessions.
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Table 8
BAT Baseline SUDs Results for Repeated Measures ANOY A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig.

4751.230
11903.472

1
26

4751.230
457.826

10.378

.003

21423.572
3791.429
18795.405

1.463
1.463
38.048

14639.757
2590.866
493.992

29.636
5.245

.000
.017

The therapist rating for severity of the subject's phobia across conditions is
presented in Figure 8. The two groups were significantly different at posttest (Q =
.013, Table 9). The therapist's rating was significantly decreased for the treatment
group across trials.
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Th..:rnpist's Rating
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Figure 8. Therapist Rating - Change in Group Means Across Sessions.
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Table 9
Therapist Rating Results for Repeated Measures ANOV A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

dF

MS

F

Sig.

25.922
45.412

1
30

25.922
1.514

17.125

.000

18.135
6.469
37.260

1.660
1.660
49.804

10.924
3.897
.748

14.602
5.208

.000
.013

Each subject rated expected success of treatment at pretest, immediately after
treatment and posttest. Figure 9 demonstrates the changes in group means across
time on this measure. The difference was significant at posttest (Q=.036, Table 10).
5

4

---Trentment Group
...,._ Phobic Control Group

2

Subject's Rating Pretest

Subject's Rating
Trcatmc.:nt

Subjc.:ct's Rating Posttc.:st

Trial

Figure 9. Subject Rating - Change in Group Means Across Sessions.
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Table 10
BAT Subject Rating Results for Repeated Measures ANOV A
Source
Between
Subjects
Groups
Error
Within Subjects
Trials
Trials x Groups
Error

ss

DF

MS

F

Sig.

32.510
39.115

1
30

32.510
1.304

24.935

.000

8.249
4.749
37.501

1.683
1.683
50.502

4.900
2.821
.743

6.599
3.799

.005
.036

The posttest differences between all three groups were analyzed with a One
way ANOV A and multiple comparison Tukey tests. Significant overall differences
were found on FSS, specific phobia questionnaire, BAT distance, BAT SUDs,
therapist rating, and baseline SUDs (Q < .001 for each dependent measure). The two
SCL-90-R subscales were not significantly different between these groups at posttest.
The multiple comparison results demonstrated that each of the three groups were
significantly different from one another on the FSS, specific phobia questionnaire,
and therapist's rating. The treatment group was not significantly different than the
non-phobic control group on the BAT distance, SUDs, and baseline SUDs measures.
The treatment group entered the "normal" range on these measures at posttest. These
two groups continued to be significantly different on subjective and self-report
measures and the therapist's subjective measure of phobia severity.

All of the

significant posttest differences met the conservative Bonferroni critical value.
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The APS was significantly different between the groups at posttest (12

=

.049).

The non-phobic control group differed from the phobic control group on this measure
(12 = .039). The treatment group did not differ from either group on this measure.
One-sample t-tests were conducted for the differences between posttest and
follow-up scores from the treatment group. All of these tests were non-significant.
All changes that occurred between pretest and posttest were maintained at the one
month follow-up.
A Pearson Product -Moment Correlation Coefficient was conducted on the
APS score and a composite of dependent variables. Included in the composite was
the differences between pretest and posttest scores on the FSS, specific phobia
questionnaire, BAT distance and SUD's measures and the therapist's rating for
severity of phobia. These five dependent measures produced the most change for the
treatment subjects. No significant correlations were found between this composite
score and any of the APS administrations (i.e., pretest, posttest, or follow-up). The
composite score was significantly correlated with all of the individual dependent
measure differences from pretest to posttest. The subject rating of expected success
of treatment immediately following treatment (12<.00I ), at posttest (12= .001 ), and
follow-up (12=.002) was significantly correlated with

the composite score.

significance of all the above findings will be discussed in the next section.

The

CHAPTER IV
DISCUSSION
Comparison With Previous Research
Consideration of the Main Hypotheses
The results of the present study support previous evidence that one-session
exposure treatment has a significant effect on alleviating symptoms of small animal
phobia. The results are preliminary with respect to the importance of the APS m
predicting the outcome of exposure therapy.
This study utilized a modified treatment procedure based on Ost's one-session
exposure treatment (Ost 1997b, 1997a, 1989). This procedure was strictly behavioral
without any direct cognitive interventions. This study showed similar results to Ost's
in the alleviation of specific phobia symptoms even without the cognitive
interventions.
The BAT produced some progress in the phobic control group as the result of
practice and opportunities for exposure to the animal in a controlled setting. These
results remain significantly different from the changes seen in the treatment group.
Slight changes can be produced following exposure even without treatment being
offered; however, the treatment procedure produced significant changes.
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One hypothesis for the present study was that the one-session exposure
treatment would be effective for alleviating symptoms of specific phobia. In fact this
did occur and almost all subjects showed dramatic improvement from treatment. The
second hypothesis pertained to the predictive validity of the APS. This hypothesis
was not supported. The sample size was small for a correlation comparison and
further research is necessary to determine if this relationship occurs with larger
sample sizes.
Consideration of the Outcome Measures
The findings in the present investigation with respect to the BAT and the self
report measure of fear were consistent with the results produced by Ost and his
colleagues (Hellstrom & Ost, 1995; Ost et al., 1992; Ost et al., 1991, Ost; 1989). In
particular the treatment was effective in significantly reducing the behavioral
measures, i.e., BAT distance, SUDs, etc. Following treatment, the phobic treatment
group was equivalent to the non-phobic control group on BAT distance and SUDs
ratings as well as the SUDs taken at the pretest distance. The treatment subjects were
functioning in the normal range with respect to approaching the animal.

These

subjects also reported experiencing the same amount of anxiety in the presence of the
animal as the non-phobic subjects. The results from the non-phobic control group
allow for a measure of clinical significance to determine if the phobic subjects are
now functioning within the normal range. This was found to be particularly true with
the BAT and less so with the self-report questionnaires.

The improvement in
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behavioral measures may have been influenced by the type of treatment that was
used, i.e., a behavioral treatment. Possibly the self-report measures utilized were not
sensitive enough to detect the quick reduction in symptoms. The subjects may not
have encountered the feared animal between treatment and posttest/follow-up to test
the effects of treatment and determine their progress with respect to answering the
questionnaires.
A conflicting finding between the present study and previous research
conducted by Ost ( 1989) pertains to subject drop out rate.

This study had eight

subjects who dropped out prior to the treatment session, whereas Ost reports no
dropout over the course of several studies. Perhaps this study differed from the other
studies in the basic description given about the treatment procedure, which may have
impacted retention. Another possible explanation is that Ost may utilize a different
definition for classifying dropout subjects.
Almost all subjects completed the entire treatment procedure.

The

termination criteria involved handling the animal for at least 60 seconds while
reporting little or no anxiety. Sixteen out of twenty of the subjects in the present
study were able to meet that criterion.
The SCL-90-R anxiety and phobic anxiety subscales did not demonstrate
change from pretest to posttest between groups m this study.

These are global

measures of anxiety. Perhaps these scales are not reactive enough to detect anxiety to
specific stimuli such as animals. This would be particularly true when the animal is
not encountered on a regular basis because the SCL-90-R only covers symptoms from

the past week. If the subject did not come into contact with the animal during the
week, than no symptoms would be present.
Limitations of the Study
One limitation to the present study is that the control and treatment subjects
were not randomly assigned. However, random assignment is less essential for a
repeated measurement design that measures within subject changes over time or
trials. As well, the groups were equivalent on the dependent measures at pretest,
which makes random assignment less of a concern. The extensive lengths of the
phobia duration (5 to 65 years) make it unlikely that such dramatic change in
symptoms of specific phobia would have occurred without the treatment.
Furthermore, spontaneous recovery is unlikely with this diagnosis.

The control

subjects received exposure to the animal during the BAT sessions and did not
improve significantly from baseline.

The treatment procedure itself produced

clinically .significant improvement as measured by structured interviews, self-report
and objective measures. The factors listed above support the validity of the present
study regardless of the lack of random assignment.
Another concern along with random assignment is the issue of selection bias.
A majority of the treatment subjects were college students and most of the phobic
control subjects were from the surrounding communities. This created a difference
between the two phobic group means pertaining to age and length of fear. Almost all
of the non-phobic control subjects were college students as well.

Despite these
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differences, the groups were equivalent at baseline on the dependent measures.
Therefore, selection bias does not seem to have effected the results of this study.
Future studies should utilize random assignment to ensure the equivalency between
groups on basic characteristics such as age, length of fear, severity of fear, etc. and to
avoid issues of selection bias.
A second limitation of the present study is the small sample size. The sample
size in this study is similar to the previous one-session exposure work conducted by
Ost; however, a larger sample size is needed to specifically assist with answering the
question pertaining to the correlation between the APS and treatment outcome
specifically. Future research should continue to assess this relationship.

Appendix A
Observer Data Collection Form for Behavioral Avoidance Test (BAT)
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Observation Form for Behavioral Avoidance Test (BAT)
Subject Number: _______ Date: ____ Observer: _______
Session (circle one): Baseline

Treatment

Posttest

Follow-Up

Duration Measure: Time in seconds from beginning of the BAT until the SUDS.
Total Trial One: ----

Total Trial Two: -----

Contact time: ----(3 minute cut-off)

Contact time: -----(3 minute cut-off)

Distance Measure: Number on last fully passed mark or on BAT criteria.
Trial One: ------

Trial Two: ------

SUDS: Rating given by the subject following the assistant's final verbal prompt.
Trial One: -----

Trial Two: -----

Baseline Level (Step ) SUDS: ----

Comments:

The subject's response to the BAT and level of severity Trial One:

Trial One: ---------------------------

Trial Two:
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Subject's rating scale:
Having now been given the explanation for the treatment (Having now received the
treatment), please express your current level of confidence regarding the treatment
outcome:

I = Extremely skeptical that the treatment will have positive effects
2 = Somewhat skeptical that the treatment will have positive effects.
3 = Withholding judgment; equally confident and skeptical.
4 = Somewhat confident that the treatment will have positive effects.
5 = Extremely confident the treatment will have positive effects.

Subject's rating for expected success of treatment: ____

1 = Symptom free and not disabling.
2 = Slightly severe and disabling.
3 = Moderately severe and disabling.
4 = Excessively severe and disabling.
5 = Extremely severe and disabling.
Assistant's rating for severity of phobia:�---

Third Session Only:
Watched Video: Yes No

Wanted to Practice: Yes No

Appendix B
Human Subjects Institutional Review Board and Institutional
Animal Care and Use Committee Approval Forms
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WESTERN MICHIGAN UNIVERSITY
Date: 30 June 1997

To:

Richard Spates, Principal Investigat
Ellen Koch, Student Investig or
� t

Re:

Changes to HSIRB Project Number 96-05-01

From: Richard Wright, Chao�oJ

This letter will serve as confirmation that the changes to your research project "The Treatment
Utility of the Arousal Predisposition Scale in Predicting Outcome of Exposure Therapy with
Small Animal Phobias" requested in your memo dated 26 June 1997 have been approved by the
Human Subjects Institutional Review Board.

The conditions and the duration of this approval are specified in the Policies of Western
Michigan University.

Please note that you may only conduct this research exactly in the form it was approved. You
must seek specific board approval for any changes in this project. You must also seek reapproval
if the project extends beyond the termination date noted below. In addition if there are any
unanticipated adverse reactions or unanticipated events associated with the conduct of this
research, you should immediately suspend the project and contact the Chair of the HSIRB for
consultation.
The Board wishes you success in the pursuit of your research goals.
Approval Termination:

9 April 1998

Kalamazoo, Michigan 49008-5162

Research and Sponsored Programs

616 387-8270
FAX: 616 387-8276
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WESTERN MICHIGAN UNIVERSllY
Date:

15 September 1997

To:

Richard Spates, Principal Investigator
Ellen Koch, Student Investi ator
Jane Luterek, Studeny: vesf

From: Bruce Bejcek, Ch&'
Re:

Changes to IAC

This letter will serve as confirmation that the changes to your research project "The Treatment
Utility of the Arousal Predisposition Scale in Predicting Outcome of Exposure Therapy with
Small Animal Phobias" requested in your memo dated 7 September 1997 have been approved by
the Institutional Care and Use Committee (IACUC).
The conditions and the duration of this approval are specified in the Policies of Western
Michigan University.
The IA CUC wishes you success in the pursuit of your research goals.
Approval Termination:

15 September 1998

Appendix C
Recruitment Flyer and Script
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Small Animal Phobia/Fear Treatment Study

Clinical researchers at Western Michigan University are
currently seeking individuals to participate in a treatment
study that will evaluate the treatment of the
following s1nall animal fears:
Snakes
Spiders
Rats/Mice
Crawling Insects
If you currently experience intense fear or avoidance in the
presence of the above anin1als you may be eligible for
participation in this study. Participation will involve answering
several questionnaires as well as participating in three additional
sessions at WMU. You n1ust be at least 18 years old to
participate. If you would like to find out n1ore about this study
please contact Ellen Koch at 387-8303 ext. 1. Please leave a
message indicating your nan1e, phone number
and the best ti1ne to reach you.
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Recruitment Script
Introduce yourself-Today, I am going to talk to you about two different research
studies which are being conducted through the clinical psychology department at
Western Michigan University in hopes of recruiting participants for each of these
studies.
The first study is Ellen Koch's Small Animal Phobia Treatment Study. This study is
for individuals who experience intense fear or avoidance to any of the following
small animals: snake, spider, rat, mice, or crawling insects. This study is a treatment
study so participants will be receiving treatment for their phobias. It entails filling out
questionnaires and answering several questions, along with receiving treatment. It's
four sessions long, with the first, third, and fourth session lasting no more than an
hour in length and the second session, which is the treatment session, lasting no more
than three hours. However, this session can be completed in a shorter amount of time.
If you are interested in participating in this study or would like to learn more about
the study, please take a card. The card has the research line phone# on it, so just call
this number and leave your name, phone#, and the best time to call and Ellen will get
back to you. (Pass the cards out)
The second study that I wanted to tell you about is Jane Luterek' s Small Animal
Phobia Assessment Study for Non-Phobic Participants. This study is for individuals
who do NOT experience intense fear or avoidance to any of the following small
animals: snakes, spiders, rats, mice, and crawling insects. This study entails filling out
questionnaires and answering several questions. It's lasts two sessions and each
session is no more than two hours in length. There is also a 1 in 15 chance of winning
$25.00.
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If you are interested in participating in this study or would like to learn more, please
write down your name, phone#, and the best time to call and Jane will get in contact
with you. If you feel uncomfortable leaving your name and phone#, you can leave a
confidential message at the phone# listed on the bottom of this page and Jane will get
back to you. (Pass the recruitment lists around). Thank you for your time.

Appendix D
Research Commons Area Room Layout
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Appendix E
First Session Instructions
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First Session Instructions
The file needs the following forms:
Informed Consent - 2 copies
Screening Questionnaire
Arousal Predisposition Scale (APS)
Structured Clinical Interview for DSM-IV (SCIO)
Symptom Checklist 90 - Revised (SCL-90-R)
Fear Survey Schedule (FSS)
Specific Fear Questionnaire (i.e., Spider Phobia Questionnaire, Snake Phobia
Questionnaire, etc.)
BAT Observation Data Form
The questionnaires are administered in the order listed above.
•

Describe what is going to happen today. / will be asking you several questions
and I will ask you to.fill out a.few ,,,wstionnaires. Do you have any questions
before we get started?

•

Have the subject read and sign one informed consent and give the subject a
second copy to keep.

•

Ask the subject the questions on the screening questionnaire. If the subject
answers in a way that leads to exclusion (indicated by the italic instructions on the
form after each question), then ask for more details to determine that the subject
should be appropriately excluded. For example, answering yes to chronic
headaches leads to exclusion, determine that the headaches are severe (i.e.,
migraines) to appropriately exclude the subject.

•

Give the subject the APS to complete on their own.

•

Administer the SCID to the subject. Any item endorsed on the SCID should lead
to further questions, i.e., describe, explain, etc. The subject qualifies for this
study if he/she meets the criteria for specific phobia (with a lenient E criterion) on
the SCID and does not meet diagnostic criteria for Panic Disorder, Somatoform,
or PTSD related to the specific animal. The subject is also excluded if he/she

endorses any of the Psychoticism items (again question any endorsed items to
determine if psychosis is actually present).
While the subject is completing the following questionnaires, score the APS and the
SCID.
•

Give the subject the SCL-90-R to complete.

•

Give the subject the FSS to complete.

•

Give the subject the Specific Fear Measure to complete.

Scoring the APS- the 12 statements are scored in ascending sequence, with "Never"
equal to 1 up to "Always" equal to 5, except for number 1, which is reverse scored.
The subject's score is the sum of the 12 responses.
Notify the subject that he/she qualifies for the study.
Begin the Behavioral Avoidance Test (BAT)
•

State, "In a moment I would like you to enter tl,e ne.x:t room.for the behavior
assessment. The.feared animal is in a cage against the.far wall. Wlten you
enter the room approach the animal as much as you possibly can and pick the
animal up gently when you are ready. I will indicate when you have held the
animal long enough. The animals utilized in this study are not likely to harm
you; they are the most innocuous animal of their kiml However, there is no
guarantee. I am prepared to assist you in tl,e event of any problems." Go into
the hallway and begin timing when he/she enters the room. When the subject
stops state, "Are you sure that is as.far as you can go now?" When the subject
stops following this statement or if the animal is contacted, stop the stopwatch.
Ask for a SUDS rating by stating, "On a Oto WOscale where I 00 is the most
anxious you have ever been and 0 is the least anxious you have ever been,
where are you right now with that scale in mind?" Record the SUDS, duration
(beginning to stopping point or initial contact) and distance (stopping point
according to the BAT steps) on the BAT sheet.
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•

Walk out of the room and when in the hallway state, "Would you like to try again
to see how far you can go?" The subject may choose to try again. If so state,
"Approach the animal as much as you possibly can and pick the animal up
gently when you are ready. I will indicate when you have held the animal long
enough." Repeat the BAT steps outlined above.

•

Return to the middle room and state, "As stated in the informed consent, the
treatment procedure invoh•es gradually approaching and touching the/eared
animal. The animal will remain in a cage the entire time and the therapist will
demonstrate each task prior to you being asked to complete the task. The
therapist will never do anything unplanned in the therapy room." Read the
question and five responses on the back of the BAT recording sheet (expected
success of treatment) and ask the subject to select one of the five choices.

•

Rate the severity of the subject's reaction to the BAT.

•

Schedule a treatment session with a therapist. Thank the subject for coming in
today.

FINISHED!!

Appendix F
Behavioral Avoidance Test Distance Scoring Steps
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Behavioral Avoidance Test Distance Scoring Steps
1

Does not enter the room.

2

Completely crosses the line at number 1.

3

Completely crosses the line at number 2.

4

Completely crosses the line at number 3.

5

Completely crosses the line at number 4.

6

Completely crosses the line at number 5.

7

Completely crosses the line at number 6.

8

Completely crosses the line at number 7.

9

Completely crosses the line at number 8.

10

Completely crosses the line at number 9.

11

Completely crosses the line at number 10.

12

Completely crosses the line at number 11.

13

Completely crosses the line at number 12.

14

Completely crosses the line at number 13.

15

Completely crosses the line at number 14.

16

Touches the outside of the animal cage.

17

Touches the inside of the animal cage.

18

Touches the bottom of the animal cage.

19

Touches the animal for 0- 4 seconds not continuously.

20

Touches the animal for less than 4 seconds continuously.

21

Touches the animal for 5- 19 seconds not continuously.

22

Touches the animal for 20- 60 seconds not continuously.

23

Touches the animal for 5- 19 seconds continuously.

24

Touches the animal for 20- 39 seconds -continuously.

25

Touches the animal for 40 - 59 seconds continuously.

26

Touches the animal for 60 seconds or more continuously.

27

Picks up the animal for 1- 19 seconds.

28

Picks up the animal for 20 - 39 seconds.

29

Picks up the animal for 40 - 59 seconds.

30

Picks up the animal for 60 seconds or more.

Appendix G
Informed Consent Form
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Informed Consent for Participation in an Investigation
Western Michigan University
Department of Psychology
Principal Investigator: C. Richard Spates, Ph.D.
Research Associate: Ellen I. Koch, B.A.
I have been invited to participate in a research project entitled "The Treatment Utility
of the Arousal Predisposition Scale in Predicting Outcome of Exposure Therapy with
Small Animal Phobias." I understand that this research is intended to study the effects
of arousal on one-session exposure treatment outcome as well as the effectiveness of
the Arousal Predisposition Scale in determining degrees of arousal. I also understand
that the treatment will be provided by a trained therapist under the supervision of a
fully licensed clinical psychologist. I further understand that this study is Ellen I.
Koch's thesis project.
My consent to participate in this project indicates that I understand I will be asked to
attend four sessions of no more than three hours each in length. All sessions will be
conducted at Western Michigan University's North Hall, Research Commons Area.
The first session will involve completing two questionnaires, the Arousal
Predisposition Scale and a screening questionnaire and one diagnostic interview,
Structured Clinical Interview for Diagnosis to determine if I qualify for the study. If
the questionnaires and interview indicate that I do not qualify, then I will be provided
with a therapist referral list. The second part of the first session wiII involve
completing three more questionnaires, the Fear Survey Schedule, the Symptom
Checklist-90, and a specific fear measure and a Behavioral Avoidance Test. The
Behavioral Avoidance Test will consist of attempting to come as close to or in contact
with the animal that I fear. I understand that I will also he asked to rate the amount of
anxiety I am feeling on a 0-100 scale and my expected success for treatment on a 1-5
scale. The second session will involve a treatment procedure that will be only one
session and a maximum of 3 hours in length. I understand that during this treatment
procedure the therapist will gradually assist me in approaching and touching the
feared animal. I also understand that the feared animal will be in the therapy room
throughout treatment. I will be asked to rate my level of discomfort throughout
treatment. The third session will involve completing four questionnaires, the Fear
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Survey Schedule, the Arousal Predisposition Scale, Symptom Checklist-90-Revised,
and a specific fear measure, the Behavioral Avoidance Test and rating of discomfort
and treatment success. The final session will be the same as the third session and
occur at least one month following the second session. I understand that the
Behavioral Avoidance Test and the entire treatment session will be videotaped.
As in all research, there may be unforeseen risks to the participant. If an accidental
injury occurs, appropriate emergency measures will be taken; however, no
compensation or treatment will be made available to me except as otherwise specified
in this consent form. I understand that one potential risk of my participation in this
project is that I may be emotionally upset in the presence of the feared animal (during
the Behavioral Avoidance Test and treatment). I understand, however, that Ellen
Koch and the trained therapists are prepared to terminate the treatment session and
provide crisis counseling should I become significantly upset. Furthermore, they are
prepared to make a referral if I need further counseling about this topic. I will be
responsible for the cost of therapy ifl choose to pursue it. Should I receive a bite
from the animal, I understand that the research assistants will offer immediate first aid
treatment and refer me to emergency medical personnel for further evaluation. I will
be responsible for any medical costs from this evaluation.
One way in which I may benefit from this study is to eliminate my fear of the specific
animal. This treatment has been shown to be effective for others with small animal
phobias similar to mine. I also understand that others with small animal phobias may
benefit from the knowledge that is gained from this research.
I understand that the information collected fro·m me is confidential. That means that
my name will not appear on any papers on which this information is recorded. The
forms will all be coded, and Ellen Koch will keep a separate master list with the
names of participants and the corresponding code numbers. Once the data are
collected and analyzed, the master list will be destroyed. All other forms will be
retained for three years in a locked file in Ellen Koch's office.
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I understand that I may refuse to participate or quit at any time during the study
without prejudice, penalty or risk of any loss of service or opportunity I would
otherwise have. If I have any questions or concerns about this study, I may contact
either Ellen Koch at 387-8303 ext. 1 or Dr. Richard Spates at 387-8332. 1 also may
contact the Chair of Human Subjects Institutional Review Board at 387-8293 or the
Vice President for Research at 387-8298 if questions or problems arise during the
course of the study. My signature below indicates that I understand the purpose and
requirements of this study and that I agree to participate.

Signature

Date

Appendix H
Screening Questionnaire
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Screening Questionnai re
Subject Number: ______

Date: -----

Assistant: ______

What specific small animal fear are you seeking treatment for (circle one)?
Snake

Spider

Rat/Mouse

Crawling Insect (which type of insect?)

Have you had this fear for over 6 months?

Yes

No

If yes, how long? __

Answering No lead,; to exclusion from the study.

Do you have a similar fear of other animals, objects, or situations ?

Yes

No

If yes, specify the animal, object or situation.
Have you ever had a history of the following conditions:
Seizure

Yes

No

Neurological Problem

Yes

No

Ulcer

Yes

No

Heart Disease

Yes

No

Lung Disease

Yes

No

Recurring Chest Pain

Yes

No

Stroke

Yes

No

Chronic Headache

Yes

No

Answering Yes to any qf the ahove lead\· to excl11siu11_fi·om the study.

Are you taking any medications ?

Yes

No

If yes, medication name, dosage amount, and length of time taking each medication.
Are any of the above medications taken for your phobic condition?

Yes

If yes, are they working?
Answering Yes leads to exclusion 1111less medications are discontinued

No
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Subject Number: _____

Date: -----

Assistant: ------

Are you currently receiving treatment specifically for your phobic condition?
Yes

No

If yes, please specify what the treatment consists of
Answering Yes leads to exclusion.from this study.

Do you feel you use drugs or alcohol to help relieve anxiousness caused by your
phobia?

Yes

No

Are you avai !able for three more sessions over the next two months ?

Yes

No

Answering No lead�- to exclusion.
Do you want to get rid of your animal fear?

Yes

No

If yes, are you willing and prepared to tolerate some anxiety during treatment?
Yes

No
Answering No lo either question leads to exc/11sionfrom this study.

Are you currently receiving any benefits (i.e., insurance compensation, threat of a
legal claim, etc.) due to your phobia ?

Yes

No

Answering Yes leads· to excl11sio11.f rom this st11dy.
Do you foresee any negative consequences occurring if your phobia is successfully
treated?

Yes

No
Answering Yes lead,· to exc/11sio11.fiw11 this study.

Appendix I
Treatment Session Instructions
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Treatment Session Instructions
Session Checklist:
Treatment Data Collection Form
BAT Form
Treatment Session Guidelines
BAT Steps
Prior to beginning treatment review the following information with the subject:
Teamwork is an important component.for carrying out tl,e treatment. Bot/, you
and the therapist have equal responsibility.for acl,ieving a good result. This kind of
therapy is hard work and can only he successful ff you .fu(fill your part of the
teamwork. The treatment involves a series of steps initially completed hy the
therapist and then by you. Tl,e tl,erapist will never do anything unplanned in the
therapy rooni The therapist will describe what will happen, demonstrate it, and
finally ask you to complete the step. Interacting with the.feared animal in a
controlled way enables you to realize that the consequences you fear may happen
do not occur. You may ask.for a break by saying, "prmse." When you say pause,
the therapist will stop the current step whatever it may he. ff you stop completing a
step without saying "pause", the therapist will encourage you to complete the step
and say "pause" (f you would like a hreak. Think ,�f the 1110.,·t anxiety-arousing
situation you have ever experienced in relation to this animal. T!,is is equivalent to
100 on the 0-100 scale. An increase ,�f anxiety is not a goal ,�{treatment, but is
considered a momentary side effect.
After explaining these guidelines for treatment, ask the subject to tell you what is
going to happen during treatment. This allows you to clarify any misconceptions.
Also, ask the subject if he/she has any questions.
BEGIN TREATMENT
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BAT Instructions following treatment:
Approach the animal as much as you possibly can and pick the animal up gently
when you are ready. The therapist will indicate when you have held the animal
long enough.
Are you sure that is as far as you can go now?
Get a SUDS rating from the stopping point and record duration (from beginning until
SUDS or contact with the animal) and distance (according to the BAT steps).
After completing the initial BAT, walk out of the room and say,
Would you like to try again to see lwwfar you can go?
Repeat the above steps if the subject would like to try again.
Following the last BAT trial, exit the room. Ask the subject to reenter the room (to
their baseline level stopping point), and provide a SUDS level at the baseline point.
Ask the subject to rate their subjective expected success of treatment and you rate the
severity of their reaction to the BAT.

Appendix J
Treatment Step Instructions and Data Sheets
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Treatment Steps: Snake
1. Therapist and subject progress from the starting point to the cage with the subject
holding the therapist's arm if necessary (Record SUDS at Each Number).
2. Touching the outside of the container (10 seconds).
a. Therapist touches with the subject behind the. therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

3. Touching the container opening with fingertips inside the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

4. Touching the bottom of the container, hand on bottom of the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
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d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f.

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

5. Touching (two fingers) the feared animal (3 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f.

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

6. Subject touches the animal for greater periods of time (therapist demonstrate each
time interval if necessary)
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
7. Subject cups the animal underneath with one hand (Demonstrate if necessary)
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
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8. Therapist picks up the animal and holds it while the subject touches the animal
with two fingers for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
9. Therapist picks up the animal and holds it while the subject touches the animal
with one full hand for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
10. Therapist picks up the animal and holds it with one hand while the subject holds
the animal with two hands for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
11. Subject picks up the animal with both hands for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
12. Subject picks up the animal for more than 60 seconds (3 minute cut-oft) (Record
Duration and SUDS).

Subject Number:
Step
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Snake Treatment Session Data Form

Therapist:

Date:

SUDS 1

Animal-3"
Animal-60"
Cuppina Undemeath-60"
Touch-Therapist Hold-60"
Touchina One Hand - 60"
Touch Two Hands - 60"
Pick up animal-60"
Pick up animal-60"+ (time)
00

Treatment Start Time:

End Time:

Total Duration of Treatment:
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Treatment Steps: Spider
1. Therapist and subject progress from the starting point to the cage with the subject
holding the therapist's arm if necessary (Record SUDS at Each Number).
2. Touching the outside of the container (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f.

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

3. Touching the container opening with fingertips inside the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f.

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

4. Touching the bottom of the container, hand on bottom of the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
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d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f.

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

5. Placing the spider in a cup using a card to move the spider.
a. Therapist demonstrates with the subject behind the therapist.
b. Therapist demonstrates with the subject watching.
c. Therapist demonstrates with the subject touching the therapist's elbow.
d. Therapist demonstrates with the subject touching the therapist's forearm.
e. Therapist demonstrates with the subject touching the therapist's hand.
f.

Subject completes with the therapist touching the subject's hand.

g. Subject completes with the therapist touching the subject's forearm.
h. Subject completes with the therapist touching the subject's elbow.
1.

Subject completes with the therapist behind the subject. (SUDS)

6. Chase the spider by touching the spider with two fingers (3 seconds)
a. Therapist demonstrates with the subject behind the therapist.
b. Therapist demonstrates with the subject watching.
c. Therapist demonstrates with the subject touching the therapist's elbow.
d. Therapist demonstrates with the subject touching the therapist's forearm.
e. Therapist demonstrates with the subject touching the therapist's hand.
f.

Subject completes with the therapist touching the subject's hand.

g. Subject completes with the therapist touching the subject's forearm.
h. Subject completes with the therapist touching the subject's elbow.
1.

Subject completes with the therapist behind the subject. (SUDS)
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7. Chase the spider for increasing periods of time (Therapist demonstrate each time
interval if necessary)
a. 10 seconds
b. 20 seconds
c. 30 seconds (SUDS)
8. Touching (two fingers) the feared animal (3 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f.

Subject touches with the therapist touching the subject's hand.

g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
1.

Subject touches with the therapist behind the subject. (SUDS)

9. Subject touches the animal for greater periods of time (Therapist demonstrates
each time intervals if necessary)
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
10. Subject cups the animal with both hands (Therapist demonstrate)
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
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11. Subject picks up the animal with both hands for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds
12. Subject picks up the animal for more than 60 seconds (3 minutes cut-oft)
(Record Duration and SUDS).

Spider Treatment Session Data Form

Subject Number: ______

Date: ______

Therapist: _____ ____

I SUDS 1

Step

1
-2
3
4
5
-6
-7
-8
-9
10
11
12
13
14
15

Touching Outside of Cage
Touching Inside of Cage
Touching Bottom of Cage
Cue and Card
Chasing Animal-30"
Touching Animal-3"
Touching Animal-60"
Cueeing-60"
Pick ue animal-60"
Pick up animal-60"+ (time}
t.,J

Treatment Start Time:

End Time:

Total Duration of Treatment:

Treatment Steps: Rat/Mouse
1. Therapist and subject progress from the starting point to the cage with the subject
holding the therapist's arm if necessary (Record SUDS at Each Number).
2. Touching the outside of the container (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
3. Touching the container opening with fingertips inside the cage ( 10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
4. Touching the bottom of the container, hand on bottom of the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
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d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
5. Touching (two fingers) the feared animal (3 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SlJ DS)
6. Subject touches the animal for greater periods of time (therapist demonstrate each
time interval if necessary)
a. IO seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
7. Subject cups the animal over the top with one hand (Demonstrate if necessary)
a. IO seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
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8. Therapist picks up the animal and holds it while the subject touches the animal
with two fingers for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
9. Therapist picks up the animal and holds it while the subject touches the animal
with one full hand for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
10. Therapist picks up the animal, gives it to the subject while still holding it with one
hand while the subject holds the animal with two hands for increasing periods of
time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
11. Subject picks up the animal with both hands for increasing periods of time
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
12. Subject picks up the animal for more than 60 seconds (3 minute cut-off) (Record
Duration and SUDS).

Rat/Mouse Treatment Session Data Form

Subject Number: ______
Step

------------

1
2
3
4
5

Date: _______

Therapist:

SUDS1

8
9
10
11
12
13
14
15

Holdina Animal - 60"
Pick Up Animal - 60"
Pick Up Animal - 60"+ (time)
00
-..J

Treatment Start Time:

End Time:

Total Duration of Treatment:
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Treatment Steps: Crawling Insect
1. Therapist and subject progress from the starting point to the cage with the subject
holding the therapist's arm if necessary (Record SUDS at Each Number).
2. Touching the outside of the container (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
3. Touching the container opening with fingertips inside the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
4. Touching the bottom of the container, hand on bottom of the cage (10 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.

d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
5. Touching (two fingers) the feared animal (3 seconds).
a. Therapist touches with the subject behind the therapist.
b. Therapist touches with the subject watching.
c. Therapist touches with the subject touching the therapist's elbow.
d. Therapist touches with the subject touching the therapist's forearm.
e. Therapist touches with the subject touching the therapist's hand.
f. Subject touches with the therapist touching the subject's hand.
g. Subject touches with the therapist touching the subject's forearm.
h. Subject touches with the therapist touching the subject's elbow.
i. Subject touches with the therapist behind the subject. (SUDS)
6. Subject touches the animal for greater periods of time (therapist demonstrate each
time interval if necessary)
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
7. Subject cups the animal underneath with one hand (Demonstrate if necessary)
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
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8. Therapist picks up the animal and holds it while the subject touches the animal
with two fingers for increasing periods of time.
a. IO seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
9. Therapist picks up the animal and holds it while the subject touches the animal
with one full hand for increasing periods of time.
a. IO seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
10. Therapist picks up the animal, gives it to the subject while still holding it with one
hand while the subject holds the animal with two hands for increasing periods of
time.
a. IO seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
11. Subject pic�s up the animal with both hands for increasing periods of time.
a. 10 seconds
b. 20 seconds
c. 30 seconds
d. 60 seconds (SUDS)
12. Subject picks up the animal for more than 60 seconds (3 minute cut-oft) (Record
Duration and SUDS).
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Appendix K
Posttest and Follow-up Session Instructions
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Posttest and Follow-up Session Instructions
Session Checklist:
Arousal Predisposition Scale (APS)
Structured Clinical Interview for DSM-IV (SCID) Specific Phobia Section
Symptom Checklist 90 - Revised (SCL-90-R)
Fear Survey Schedule (FSS)
Specific Fear Questionnaire
BAT Data Form
The questionnaires are administered in the order listed above.
•

Describe what is going to happen today. I will be asking you questions and to
fill out a few questionnaires. Do you have any questions be.fore we get started?

•

Give the subject the APS to complete on their own.

Scoring the APS- the 12 statements are scored in ascending sequence, with "Never"
equal to 1 up to "Always" equal to 5, except for number 1, which is reverse scored.
The subject's score is the sum of the 12 responses.
•

Administer the specific phobia questions from the SCIO.

•

Give the subject the SCL-90-R to complete.

•

Give the subject the FSS to complete.

•

Give the subject the Specific Fear Measure to complete.

Begin the Behavioral Avoidance Test (BAT)
•

State, "In a moment I would like you to enter the next room for the behavior
assessment. When you enter the room approach the animal as much as you
possibly can and pick the animal up gently when you are ready. I will indicate
when you have held the animal long enough." Go into the hallway and begin
timing when he/she enters the room. When the subject stops state, "Are you sure
that is as far as you can go now?" When the subject stops following this
statement or when he/she contacts the animal, stop the stopwatch. Ask for SUDS
rating by stating, "On a Oto I 00 scale where I 00 is the 1110.w anxious you have
ever been and 0 is the least anxious you have ever been, where are you right
now with that scale in mind?" Record the SUDS, duration (beginning to
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stopping or contact point) and distance (stopping point according to the BAT
steps) on the BAT sheet.
•

Walk out of the room and when in the hallway state, "Woultl you like to try again
to see how far you can go?" The subject may choose to try again. If so state,
"Approach the animal as much as you possibly can and pick the animal up
gently when you are ready. I will indicate when you /,ave held the animal long
enough." Repeat the BAT steps outlined above.

•

Following the last BAT trial, exit the room. Ask the subject to reenter the room
(to their baseline level stopping point), and provide a SUDS level at the baseline
point.

•

Return to the middle room and read the question and five responses on the back of
the BAT recording sheet (expected success of treatment) and ask the subject to
select one of the five choices.

•

Rate the severity of the subject's reaction to the BAT.

Posttest Session Only:
• Ask the subject if he/she would like to view portions of his/her videotape from
treatment. If so, show clips at the beginning, middle and end of treatment. Make
a notation on the BAT form that the subject did or did not watch their video.
•

Inform the subject that he/she can come in 2x' s over the next few weeks to
interact with the animal if he/she wishes. This occurs between posttest and
follow-up sessions only. Make a notation on the BAT form for the subject's
response to this offer.

FINISHED!!

Appendix L
Non-phobic Instructions and Forms
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Western Michigan University
Department of Psychology

-{'

Principal Investigator: C. Richard Spates, Ph.D.
Research Associate: Jane Luterek, B.A.
I have been invited to participate in a research project entitled "Establishing
Norms for Treatment Outcome Comparisons with Small Animal Phobias." I
understand that this research project is intended to investigate the provisional norm of
non-phobic subjects to small animals using various assessment tools. as well as the
reliability of these assessment tools. I also understand that this study will be supervised
under a fully licensed clinical psychologist.
My consent to participate in this project indicates that I understand I will be
asked to attend two sessions of no more than two hours each. All sessions will be
conducted at Western Michigan University's North Hall, Research Commons Area.
The first session will involve completing two questionnaires, the Arousal Predisposition
Scale, and the Symptom Checklist-90-R. I will also be interviewed on several sections
of the Structured Clinical Interview for Diagnosis(SCID), along with an Addendum to
the SCID Screening Module to determine if I qualify for this study, The second part of
the first session will involve completing two more questionnaires, the Fear Survey
Schedule and a specific fear measure, along with a Behavioral Avoidance Test. The
Behavioral Avoidance Test will consist of attempting to come as close to or in contact
with the specified small animal. I understand that I will also be asked to rate the
amount of anxiety I am feeling on a 0-100 scale.
The second session will involve completing three questionnaires, the Fear
Survey Schedule, the Arousal Predisposition Scale, and the specific fear measure as
well as the Behavioral Avoidance Test and ratings of discomfort. I further understand
that this second session will occur approximately two weeks after the first session.
As in all research, there may be unforeseen risks to the participant. If an accidental
injury occurs, appropriate emergency measures will be taken; however, no
compensation or treatment will be made available to me except as otherwise specified
in this consent form. Should I receive a bite from the animal, I understand that the
research assistant will offer immediate first aid treatment and refer me to emergency
medical personnel for further evaluation. I will be responsible for any medical costs
from this evaluation.
I understand that others with specific phobia disorder may benefit from the knowledge
that is gained from this research. I also understand that I will be given a lottery ticket
with my corresponding code number on it for attending a session, even if I am unable
to complete this session. This lottery ticket will be placed in a jar from which two

lottery tickets will be drawn once this research project is completed. There will be a
total of 30 subjects in this study, which will allow me a potential 1 in 15 chance of 96
winning. The participant with the corresponding subject number will win $25.00.
I understand that the infonnation collected from me is confidential. This means that
my name will not appear on any papers on which this information is recorded. The
forms will all be coded, and Jane Luterek will keep a separate master list with the
names of the participants and the corresponding code numbers. Once the data are
collected and analyzed, the master list will be destroyed. All other forms will be
retained for three years in a locked file in Jane Luterek's office.
I understand that I may refuse to participate or quit at any time during the study
without prejudice, penalty, or risk of ·a loss of service or opportunity I would otherwise
have. If I have any questions or concerns about this study, I may contact either Jane
Luterek at 387-8307 or Dr. Richard Spates at 387-8332. I also may contact the Chair
of the Human Subjects Institutional Review Board at 387-8293 or the Vice President
for Research at 387-8298 if questions or problems arise during the course of the study.
My signature below indicates that I understand the purpose and requirements of this
study and that I agree to participate.

Signature

Date
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Small Animal Phobia Assessment Study Seeking
Non-phobic Participants
Snakes
Spiders
Rats/Mice
Crawling Insects
Clinical researchers at Western Michigan University are
currently seeking Non-Phobic individuals. This study will
evaluate the assessment tools used for the phobias of
the small animals listed above.
If you do NOT experience intense fear or avoidance in the
presence of any of the above animals you may be eligible for
participation in this study. This will involve answering several
questionnaires during two sessions (no more than two hours each)
which are scheduled approximately two weeks apart
and a chance to win $25.00. You must be at least 18 years old to
participate. If you would like more information, please contact Jane
Luterek at 387-8303, ext. 4. Please leave a message indicating your
name, telephone number, and the best time to reach you.

Small Animal Phobia Assessment Study for Non-phobic participants
Procedure for Session I

Questionnaires to be used include the following:
Arousal Predisposition Scale (APS)
Symptom Checklist 90 - Revised (SCL-90-R)
Fear Survey Schedule (FSS)
Specific Fear Questionnaire (i.e., Spider Phobia Questionnaire, etc.)
Pretest Observation Form for Behavioral Avoidance Test (BAT)
The Questionnaires will be administered in the order listed above.
Prior to beginning the Session, review their completed screening questionnaire and
the small animal the subject was assigned. Set up the smalI animal for the BAT and
get the Specific Fear Questionnaire for the small animal they have been assigned to.
Also, make sure all questionnaires needed are in the file, you 'II need to pull the
Specific Phobia Questionnaire Also, get their lottery ticket (which corresponds to
their subject number) and the stopwatch.
A) Describe what is going to happen today.
"I will be asking you some questions and I will ask you to fill out a.few
questionnaires. Do you /,ave any questions before we get started?"
B) Informed Consent have the subject read, sign and date the informed consent and
give them a copy to keep.
Master List Have the subject print their name address, and phone number next to their
subject# on the master list so we can contact them if they win the $25.
Also, ask the subject if they are receiving bonus points or any incentive for a class. If
so, ask the subject to write down their name, social security# and amount of time
which they participated in the study under their professors name on the blank page
attached to the master list. The subject will probably have a better idea of what
information we need to have to give to their professor.
C) APS - Give the subject the APS to complete on their own.
D) SCID - Give the Structured Clinical Interview for DSM-IV - Any item endorsed
on the SCID should lead to further questions, i.e., describe, explain, etc. The
subject qualifies for this study if he/she does not meet the criteria for specific
phobia disorder (with a lenient E criteria) on the SCID and the diagnostic
criteria for Panic Disorder, Somatoform Disorder, or any of the Psychoticism
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items (question any endorsed item to determine it psychosis is actually
present)
E) SCL-90-R - Give the subject the SCL-90-R to complete on their own
F) FSS - Give the subject the FSS to complete on their own.
G) Specific Fear Questionnaire - Give the subject the Specific Fear Questionnaire to
complete.
H) BAT- Begin the Behavioral Avoidance Test (BAT)
"In a moment I would like you to enter the ne.x:t room for the behavior assessment.
The small animal is in a cage against the.far wall. When you enter tlte room
approach the animal as much as you possibly can and pick the animal up gently
when you are ready. However, please do not remove the animal.from its' cage. I
will indicate when you have held it long enough. The animals utilized in this study
are not likely to harm you, they are the most innocuous animal r�f their kind.
However, there is no guarantee. I am prepared to assist you in the event of any
problems.
Go into the hallway and begin timing when he/she enters the room. When the subject
stops state, "Are you sure that is as far as you can go?" - Unless the subject makes
contact with the animal. When the subject stops moving forward following this
statement or makes contact with the animal, write down their duration measure.
Note: If the subject makes contact with the animal, write down the time when they
first made contact on the Observation Form for BAT and then write down their Full
Duration, which is when they either discontinued contact or they made contact for 60
seconds. Their Duration Measure is the time they started until the time they made
contact You will need to know the time in seconds in which they made contact for
the distance measure. So, continue running the stopwatch and stop it once they are no
longer engaged with the animal.
If the subject does not make contact with the small animal, their duration measure is
from the Start of the BAT until the subject stops making any forward motion, but it is
prior to asking the SUDs rating.
Ask for the SUDs rating by stating, "On a Oto I 00 scale where I 00 is the most
anxious you have ever been and 0 is the least anxious you have ever been, where are
you right now with that scale in mind?"
Note: If the subject does make contact with the animal, ask the SUDs immediately
after contact has been made. If they continue touching/picking up the small animal

100

ask how they are doing with that scale in mind," so you can get an accurate measure
right before they disengage contact. Use the last measure right before contact has
been disengaged. If the subject briefly makes contact with the animal enabling you to
get a SUDs during contact, ask the subject the SUDs question, then ask them to repeat
what they did and ask them to give you a rating at that point.
If the subject does not contact the animal, the SUDs rating should occur when the
subject is as far as they can go, after they have reached their stopping point. Record
the SUDs, Duration Measure, and Distance Measure (refer to the BAT scoring steps)
on the Observation Form for the BAT.
I) Walk out of the room and when in the hallway state
Would you like to try again to see /,ow.far you can go'!"
The subject may choose to try again. 1 f so state,
"Approach the animal as much as you possibly can am/ pick the animal up
gently when you are ready. I will indicate wizen you have /zeld the animal
long enough"
Repeat BAT Steps.
J) Subjectively rate the phobia severity of the subject's reaction to the BAT on a scale
of 1 to 5 with 1 being symptom free and 5 being extremely severe and disabling
(criteria on the back of the BAT Observation Form).
Note: Subjects who are rated with a 5 are excluded from the study and are referred
to Ellen's study for Phobic Subjects with the participant's consent. If the subject
chooses to do both trials consider both measures when rating the assistants rating of
phobia severity, do not rate each trial separately.
K) Get a lottery ticket with the subject's number on the ticket and have the subject
put the ticket in the lottery ticket can. Note: If the subject is unable to finish the
session for any reason they should still be given a lottery ticket to put in the ticket
can.
L) Schedule Session 2 approximately two weeks from Session I in a two hour block.
Be sure to reserve the rooms during the times selected.
Thank the subject for coming in today.
FINISHED!

101

Small Animal Phobia Assessment Study for Non-phobic participants
Procedure for Session 2
Questionnaires to be used include the following:
Arousal Predisposition Scale (APS)
Symptom Checklist 90 - Revised (SCL-90-R)
Fear Survey Schedule (FSS)
Specific Fear Questionnaire (i.e., Spider Phobia Questionnaire, etc.)
Pretest Observation Form for Behavioral Avoidance Test (BAT)
The Questionnaires will be administered in the order listed above.
Prior to beginning the Session, review their completed screening questionnaire and
the small animal the subject was assigned. Set up the small animal for the BAT and
get the Specific Fear Questionnaire for the small animal they have been assigned to.
Also, make sure all questionnaires needed are in the file, you'll need to pull the
Specific Phobia Questionnaire. Also, get their lottery ticket (which corresponds to
their subject number) and the stopwatch.
A) Describe what is going to happen today.
"I will be asking you some questions and I will ask you to.fill out a.few
questionnaires. Do you /,ave any questions before we get started?"
B) Master List - ask the subject if they are receiving bonus points or any incentive for
a class. If so, ask the subject to write down their name, social security# and amount
of time which they participated in the study under their professors name on the blank
page attached to the master list. The subject will probably have a better idea of what
information we need to have to give to their professor.
C) APS - Give the subject the APS to complete on their own.
D) SCL-90-R - Give the subject the SCL-90-R to complete on their own
E) FSS - Give the subject the FSS to complete on their own.
F) Specific Fear Questionnaire - Give the subject the Specific Fear Questionnaire
to complete.
G) BAT- Begin the Behavioral Avoidance Test (BAT)
"In a moment I would like you to enter the ne..'l:t room for the behavior assessment.
The small animal is in a cage against the.far wall. When you enter the room
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approach the animal as much as you possibly can and pick the animal up gently
when you are ready. However, please do not remove the animal.from its' cage. I
will indicate when you have held it long enough.
Go into the hallway and begin timing when he/she enters the room. When the subject
stops state, "Are you sure that is as.far as you can go?" - Unless the subject makes
contact with the animal. When the subject stops moving forward following this
statement or makes contact with the animal, write down their duration measure.
Note: If the subject makes contact with the animal, write down the time when they
first made contact on the Observation Form for BAT and then write down their Full
Duration, which is when they either discontinued contact or they made contact for 60
seconds. Their Duration Measure is the time they started until the time they made
contact. You will need to know the time in seconds in which they made contact for
the distance measure. So, continue running the stopwatch and stop it once they are no
longer engaged with the animal.
If the subject does not make contact with the small animal, their duration measure is
from the Start of the BAT until the subject stops making any forward motion, but it is
prior to asking the SUDs rating.
Ask for the SUDs rating by stating, "On a O to 100 scale where 100 is the most
anxious you have ever been and O is the least anxious you have ever been, where are
you right now with that scale in mind?"
Note: If the subject does make contact with the animal, ask the SUDs immediately
after contact has been made. If they continue touching/picking up the small animal
ask how they are doing with that scale in mind," so you can get an accurate measure
right before they disengage contact. Use the last measure right before contact has
been disengaged. If the subject briefly makes contact with the animal enabling you to
get a SUDs during contact, ask the subject the SUDs question, then ask them to repeat
what they did and ask them to give you a rating at that point.
If the subject does not contact the animal, the SUDs rating should occur when the
subject is as far as they can go, after they have reached their stopping point. Record
the SUDs, Duration Measure, and Distance Measure (refer to the BAT scoring steps)
on the Observation Form for the BAT.
H) Walk out of the room and when in the hallway state
Would you like to try again to see lwwfar you can go?"
The subject may choose to try again. If so state,
"Approach the animal as much as you possibly can and pick the animal up
gently when you are ready. I will indicate when you have held the animal
long enough"
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Repeat BAT Steps.
I) Baseline BAT Measure- Walk out of the BAT room and check the subject's BAT
Distance Measure from the first session. If the subject completed two trials, only
look at the second trial. Compare this measure to the subject's distance measure on
the BAT for the second session. Once again, if the subject completed two trials, only
consider the second trial. If these two measures are the same, you do not have to do a
baseline measure. However, if they are different, you will need to do a baseline
measure.
In the hallway state,
"Now I would like you to go to (baseline measure) like you did during the
_first session and see how you are.feeling at that point" Get a SUDs rating at this
point.
J) Subjectively rate the phobia severity of the subject's reaction to the BAT on a scale
of 1 to 5 with 1 being symptom free and 5 being extremely severe and disabling
(criteria on the back of the BAT Observation Form).
Note: Subjects who are rated with a 5 are excluded from the study and are referred
to Ellen's study for Phobic Subjects with the participant's consent. If the subject
chooses to do both trials consider both measures when rating the assistants rating of
phobia severity, do not rate each trial separately.
K) Get a lottery ticket with the subject's number on the ticket and have the subject
put the ticket in the lottery ticket can. Note: If the subject is unable to finish the
session for any reason they should still be given a lottery ticket to put in the ticket
can.
Thank the subject for coming in today.
FINISHED!

Appendix M
Table A: Group Means and Standard Deviations for Self-Report Questionnaires
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Table A: Group Means Across Conditions for Questionnaires
TREATMENT GROUP
Mean(SD)

PHOBIC CONTROL

NON-PHOBIC

GROUP

GROUP

Mean(SD)

Mean(SD)

Arousal Predisposition Scale(APS)
Pretest

31.0(7.10)

32.77(7.96)

30.13(5.41)

Posttest

29.15(6.55)

33.46(6.95)

27.90(6.65)

Follow-up

29.78(5.90)

NA

NA

Fear Survey Schedule(FSS)
Pretest

4.65(.90)

5.22(1.00)

2.30(.39)

Posttest

3.05(.69)

4.67(.81)

2.25 (.43)

Follow-up

3.02(.81)

NA

NA

Specific Fear Questionnaire(Weighted Scores)
Pretest

20.47(7.70)

23.40(8.60)

5.65(2.94)

Posttest

11.45(4.33)

20.85(7.74)

5.55(3.36)

Follow-up

10.52(5.38)

NA

NA

SCL-90-R Anxiety Subscale
Pretest

49.50(9.52)

50.23(9.58)

48.43(9.49)

Posttest

46.95(10.52)

50.0(9.91)

49.20(9.52)

45.0(8.10)

NA

NA

Follow-up

SCL-90-R Phobic Anxiety Subscale
Pretest

50.85(7.94)

52.38(8.38)

46.87(4.38)

Posttest

49.80(7.52)

50.92 (7.20)

47.40(5.28)

Follow-up

49.0(6.99)

NA

NA

Appendix N
Table B: Group Means and Standard Deviations for BAT Measures
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Table B: Group Means Across Conditions for BAT
TREATMENT
GROUP
Mean(SD)
Pretest
Treatment
Posttest
Follow-up
Pretest
Treatment
Posttest
Follow-up
Pretest
Treatment
Posttest
Follow-up
Pretest
Treatment
Posttest
Follow-up
Pretest
Treatment
Posttest
Follow-up

NON-PHOBIC
PHOBIC CONTROL
GROUP
GROUP
Mean(SD)
Mean(SD)
BAT Maximum Distance Score
26.20(5.34)
12.77(4.78)
NA
15.23(3.56)
27.0(4.50)
16.38(5.20)

11.70 (4.35)
28.32(3.80)
25.45(5.78)
NA
26.56(6.05)
NA
BAT SUDs Score at Maximum Distance
21.87(25.12)
56.40(21.31)
54.23(28.86)
NA
53.08(23.41)
15.17(26.70)
13.23(15.04)
56.85(20.42)
24.50(25.60)
NA
14.06(24.01)
NA
BAT SUDs Score at Baseline Distance

NA

NA

NA
NA

6.0 (I 8.59)
27.27(13.85)
5.78 (16.37)
34.62 (25.70)
8.70(12.31)
9.0(24.25)
NA
NA
Therapist's Rating for Severity of Phobia(1 to 5 scale)
1.0(0.0)
3.38(.96)
3.10(1.21)
1.58(.90)
2.85( 1.07)
NA
1.65(.75)
3.15(.80)
1.07(.25)
1.61(.92)
NA
NA
Subject's Rating for Expected Success of Treatment(1 to 5 scale)
3.50(1.10)
2.92(.86)
NA
4.58(.69)
3.15(.99)
NA
4.45(.76)
3.0(1.29)
NA
4.39(.98)
NA
NA
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